Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 116

1.

Migration of Nucleocapsids in Vesicular Stomatitis Virus-Infected Cells Is Dependent on both Microtubules and Actin Filaments.

Yacovone SK, Smelser AM, Macosko JC, Holzwarth G, Ornelles DA, Lyles DS.

J Virol. 2016 Jun 10;90(13):6159-70. doi: 10.1128/JVI.00488-16. Print 2016 Jul 1.

2.

The border-to-border distribution method for analysis of cytoplasmic particles and organelles.

Yacovone SK, Ornelles DA, Lyles DS.

Cell Tissue Res. 2016 Feb;363(2):351-60. doi: 10.1007/s00441-015-2265-x. Epub 2015 Aug 28.

3.

Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Westcott MM, Liu J, Rajani K, D'Agostino R Jr, Lyles DS, Porosnicu M.

J Virol. 2015 Aug;89(15):7944-54. doi: 10.1128/JVI.00757-15. Epub 2015 May 20.

4.

Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.

Yu N, Puckett S, Antinozzi PA, Cramer SD, Lyles DS.

J Virol. 2015 May;89(10):5250-63. doi: 10.1128/JVI.00257-15. Epub 2015 Mar 4.

5.

Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.

Blackham AU, Northrup SA, Willingham M, Sirintrapun J, Russell GB, Lyles DS, Stewart JH 4th.

J Surg Res. 2014 Apr;187(2):412-26. doi: 10.1016/j.jss.2013.10.032. Epub 2013 Oct 21.

6.

Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.

Smedberg JR, Westcott MM, Ahmed M, Lyles DS.

J Virol. 2014 Jan;88(2):777-85. doi: 10.1128/JVI.02898-13. Epub 2013 Nov 6.

7.

Preservation of dendritic cell function during vesicular stomatitis virus infection reflects both intrinsic and acquired mechanisms of resistance to suppression of host gene expression by viral M protein.

Westcott MM, Ahmed M, Smedberg JR, Rajani KR, Hiltbold EM, Lyles DS.

J Virol. 2013 Nov;87(21):11730-40. doi: 10.1128/JVI.00680-13. Epub 2013 Aug 28.

8.

Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.

Randle RW, Northrup SA, Sirintrapun SJ, Lyles DS, Stewart JH 4th.

Surgery. 2013 Dec;154(6):1323-29; discussion 1329-30. doi: 10.1016/j.surg.2013.04.050. Epub 2013 Aug 22.

9.

Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.

Lawrence TM, Wanjalla CN, Gomme EA, Wirblich C, Gatt A, Carnero E, GarcĂ­a-Sastre A, Lyles DS, McGettigan JP, Schnell MJ.

PLoS One. 2013 Jun 26;8(6):e67123. doi: 10.1371/journal.pone.0067123. Print 2013.

10.

Assembly and budding of negative-strand RNA viruses.

Lyles DS.

Adv Virus Res. 2013;85:57-90. doi: 10.1016/B978-0-12-408116-1.00003-3. Review.

PMID:
23439024
11.

Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.

Blackham AU, Northrup SA, Willingham M, D'Agostino RB Jr, Lyles DS, Stewart JH 4th.

Surgery. 2013 Mar;153(3):333-43. doi: 10.1016/j.surg.2012.09.003. Epub 2012 Oct 25.

12.

Complexes of vesicular stomatitis virus matrix protein with host Rae1 and Nup98 involved in inhibition of host transcription.

Rajani KR, Pettit Kneller EL, McKenzie MO, Horita DA, Chou JW, Lyles DS.

PLoS Pathog. 2012 Sep;8(9):e1002929. doi: 10.1371/journal.ppat.1002929. Epub 2012 Sep 27.

13.

Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.

Johnson JB, Lyles DS, Alexander-Miller MA, Parks GD.

J Virol. 2012 Sep;86(18):9929-40. doi: 10.1128/JVI.01154-12. Epub 2012 Jul 3.

14.

Vesicular stomatitis virus as a treatment for colorectal cancer.

Stewart JH 4th, Ahmed M, Northrup SA, Willingham M, Lyles DS.

Cancer Gene Ther. 2011 Dec;18(12):837-49. doi: 10.1038/cgt.2011.49. Epub 2011 Sep 2.

15.

Interplay between innate immunity and negative-strand RNA viruses: towards a rational model.

Gerlier D, Lyles DS.

Microbiol Mol Biol Rev. 2011 Sep;75(3):468-90, second page of table of contents. doi: 10.1128/MMBR.00007-11. Review.

16.
17.

Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin.

Ahmed M, Puckett S, Arimilli S, Braxton CL, Mizel SB, Lyles DS.

J Virol. 2010 Nov;84(22):12093-8. doi: 10.1128/JVI.00406-10. Epub 2010 Sep 15.

18.

Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.

Ahmed M, Puckett S, Lyles DS.

Cancer Gene Ther. 2010 Dec;17(12):883-92. doi: 10.1038/cgt.2010.46. Epub 2010 Aug 20.

19.

Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Braxton CL, Puckett SH, Mizel SB, Lyles DS.

J Virol. 2010 Apr;84(7):3552-61. doi: 10.1128/JVI.01572-09. Epub 2010 Jan 20.

20.

Interferon response and viral evasion by members of the family rhabdoviridae.

Faul EJ, Lyles DS, Schnell MJ.

Viruses. 2009 Dec;1(3):832-51. doi: 10.3390/v1030832. Epub 2009 Nov 9.

Supplemental Content

Loading ...
Support Center